Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 107, Issue , 2016, Pages 310-320

  Bickel, Fabian ^a,b   Herold, Eva Maria ^a   Signes, Alba ^a   Romeijn, Stefan ^c   Jiskoot, Wim ^c   Kiefer, Hans ^a  

^a BIBERACH UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Acidic conditions; Aggregate; Downstream processing; IgG; MAb; Reversibility; Salt

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; SODIUM CHLORIDE; TREHALOSE; UNCLASSIFIED DRUG;

ANTIBODY AGGREGATION; ANTIBODY AND IMMUNOGLOBULIN STRUCTURE, FUNCTION AND PRODUCTION; ARTICLE; BETA SHEET; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; DIFFERENTIAL SCANNING CALORIMETRY; DOWNSTREAM PROCESSING; FEASIBILITY STUDY; FLUORESCENCE SPECTROSCOPY; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; INFRARED SPECTROSCOPY; IONIC STRENGTH; MELTING POINT; PARTICLE SIZE; PH; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; SIZE EXCLUSION CHROMATOGRAPHY; SOLUBILITY; THERMOSTABILITY; TURBIDITY; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OSMOLARITY; PHOTOMETRY;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; HYDROGEN-ION CONCENTRATION; NEPHELOMETRY AND TURBIDIMETRY; OSMOLAR CONCENTRATION; PARTICLE SIZE; SODIUM CHLORIDE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TREHALOSE;

EID: 84982156313     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.07.020     Document Type: Article

References (50)

1. [1] Jing, Y., Borys, M., Nayak, S., Egan, S., Qian, Y., Pan, S.-H., et al. Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells. Process Biochem. 47 (2012), 69–75.
2. [2] Vázquez-Rey, M., Lang, D.A., Aggregates in monoclonal antibody manufacturing processes. Biotechnol. Bioeng. 108 (2011), 1494–1508.
3. [3] Wang, W., Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289 (2005), 1–30.
4. [4] McKoy, J.M., Stonecash, R.E., Cournoyer, D., Rossert, J., Nissenson, A.R., Raisch, D.W., et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 48 (2008), 1754–1762.
5. [5] Ahmadi, M., Bryson, C.J., Cloake, E.a., Welch, K., Filipe, V., Romeijn, S., et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm. Res. 32 (2015), 1383–1394.
6. [6] Ratanji, K.D., Derrick, J.P., Dearman, R.J., Kimber, I., Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 11 (2014), 99–109.
7. [7] Gagnon, P., IgG aggregate removal by charged-hydrophobic mixed mode chromatography. Curr. Pharm. Biotechnol. 10 (2009), 434–439.
8. [8] Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007), 1–26.
9. [9] Oyetayo, O.-O., Kiefer, H., Experimental model system to study ph shift-induced aggregation of monoclonal antibodies under controlled conditions. Pharm. Res., 2016.
10. [10] Fahrner, R.L., Knudsen, H.L., Basey, C.D., Galan, W., Feuerhelm, D., Vanderlaan, M., et al. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 18 (2001), 301–327.
11. [11] Zölls, S., Tantipolphan, R., Wiggenhorn, M., Winter, G., Jiskoot, W., Friess, W., et al. Particles in therapeutic protein formulations, Part 1: Overview of analytical methods. J. Pharm. Sci. 101 (2012), 914–935.
12. [12] Katayama, D.S., Nayar, R., Chou, D.K., Campos, J., Cooper, J., Vander Velde, D.G., et al. Solution behavior of a novel type 1 interferon, interferon-τ. J. Pharm. Sci. 94 (2005), 2703–2715.
13. [13] Ejima, D., Yumioka, R., Arakawa, T., Tsumoto, K., Arginine as an effective additive in gel permeation chromatography. J. Chromatogr. A 1094 (2005), 49–55.
14. [14] Filipe, V., Hawe, A., Jiskoot, W., Critical evaluation of Nanoparticle Tracking Analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27 (2010), 796–810.
15. [15] Zölls, S., Weinbuch, D., Wiggenhorn, M., Winter, G., Friess, W., Jiskoot, W., et al. Flow imaging microscopy for protein particle analysis—a comparative evaluation of four different analytical instruments. AAPS J. 15 (2013), 1200–1211.
16. [16] Kelly, S.M., Jess, T.J., Price, N.C., How to study proteins by circular dichroism. Biochim. Biophys. Acta Proteins Proteomics. 1751 (2005), 119–139.
17. [17] Micsonai, A., Wien, F., Kernya, L., Lee, Y.-H., Goto, Y., Réfrégiers, M., et al. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Proc. Natl. Acad. Sci. 112 (2015), E3095–E3103.
18. [18] Matheus, S., Friess, W., Mahler, H.-C., FTIR and nDSC as analytical tools for high-concentration protein formulations. Pharm. Res. 23 (2006), 1350–1363.
19. [19] Beechem, J.M., Brand, L., Time-resolved fluorescence of proteins. Annu. Rev. Biochem. 54 (1985), 43–71.
20. [20] Hawe, A., Sutter, M., Jiskoot, W., Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 25 (2008), 1487–1499.
21. [21] Cheng, W., Joshi, S.B., He, F., Brems, D.N., He, B., Kerwin, B.A., et al. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J. Pharm. Sci. 101 (2012), 1701–1720.
22. [22] Maggio, E.T., Use of excipients to control aggregation in peptide and protein formulations. J. Excipients Food Chem. 1 (2010), 40–49.
23. [23] Yancey, P.H., Water stress, osmolytes and proteins. Am. Zool. 41 (2001), 699–709.
24. [24] Curtis, R.A., Lue, L., A molecular approach to bioseparations: protein–protein and protein–salt interactions. Chem. Eng. Sci. 61 (2006), 907–923.
25. [25] Brümmer, W., Affinity chromatography, carriers, and ligand binding. J. Solid-Phase Biochem. 4 (1979), 171–187.
26. [26] Arakawa, T., Philo, J.S., Tsumoto, K., Yumioka, R., Ejima, D., Elution of antibodies from a Protein-A column by aqueous arginine solutions. Protein Expr. Purif. 36 (2004), 244–248.
27. [27] Flickinger, M.C., (eds.) Downstream industrial biotechnology: recovery and purification, 2013, Wiley-VCH Verlag GmbH & Co. KGaA.
28. [28] Alavattam, S., Demeule, B., Liu, J., Yadav, S., Cromwell, M., Shire, S.J., Biophysical analysis in support of development of protein pharmaceuticals. Narhi, L.O., (eds.) Biophys. Ther. Protein Dev, 2013, Springer New York, New York, NY, 173–204.
29. [29] Amin, S., Barnett, G.V., Pathak, J.A., Roberts, C.J., Sarangapani, P.S., Protein aggregation, particle formation, characterization & rheology. Curr. Opin. Colloid Interface Sci. 19 (2014), 438–449.
30. [30] Filipe, V., Hawe, A., Carpenter, J.F., Jiskoot, W., Analytical approaches to assess the degradation of therapeutic proteins. TrAC, Trends Anal. Chem. 49 (2013), 118–125.
31. [31] Arai, M., Kuwajima, K., Role of the molten globule state in protein folding. Adv. Protein Chem. 53 (2000), 209–282.
32. [32] Filipe, V., Kükrer, B., Hawe, A., Jiskoot, W., Transient molten globules and metastable aggregates induced by brief exposure of a monoclonal IgG to low pH. J. Pharm. Sci. 101 (2012), 2327–2339.
33. [33] Fink, A.L., Oberg, K.a., Seshadri, S., Discrete intermediates versus molten globule models for protein folding: characterization of partially folded intermediates of apomyoglobin. Fold Des. 3 (1998), 19–25.
34. [34] Jiskoot, W., Beuvery, E.C., de Koning, A.A., Herron, J.N., Crommelin, D.J., Analytical approaches to the study of monoclonal antibody stability. Pharm. Res. 7 (1990), 1234–1241.
35. [35] Jiskoot, W., Bloemendal, M., van Haeringen, B., van Grondelle, R., Beuvery, E.C., Herron, J.N., et al. Non-random conformation of a mouse IgG2a monoclonal antibody at low pH. Eur. J. Biochem. 201 (1991), 223–232.
36. [36] Ptitsyn, O.B., Molten globule and protein folding. Adv. Protein Chem. 47 (1995), 83–229.
37. [37] Sahin, E., Grillo, A.O., Perkins, M.D., Roberts, C.J., Comparative effects of pH and ionic strength on protein–protein interactions, unfolding, and aggregation for IgG1 antibodies. J. Pharm. Sci. 99 (2010), 4830–4848.
38. [38] Uversky, V.N., Karnoup, A.S., Segel, D.J., Seshadri, S., Doniach, S., Fink, A.L., Anion-induced folding of Staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates. J. Mol. Biol. 278 (1998), 879–894.
39. [39] Arosio, P., Barolo, G., Müller-Späth, T., Wu, H., Morbidelli, M., Aggregation stability of a monoclonal antibody during downstream processing. Pharm. Res. 28 (2011), 1884–1894.
40. [40] Arosio, P., Rima, S., Morbidelli, M., Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: From oligomers to larger aggregates. Pharm. Res. 30 (2013), 641–654.
41. [41] Queiroz, J.A., Tomaz, C.T., Cabral, J.M.S., Hydrophobic interaction chromatography of proteins. J. Biotechnol. 87 (2001), 143–159.
42. [42] Roberts, D., Keeling, R., Tracka, M., van der Walle, C.F., Uddin, S., Warwicker, J., et al. Specific ion and buffer effects on protein–protein interactions of a monoclonal antibody. Mol. Pharm. 12 (2015), 179–193.
43. [43] Majumdar, R., Manikwar, P., Hickey, J.M., Samra, H.S., Sathish, H.a., Bishop, S.M., et al. Effects of salts from the hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52 (2013), 3376–3389.
44. [44] Bhat, V., Olenick, M.B., Schuchardt, B.J., Mikles, D.C., Deegan, B.J., McDonald, C.B., et al. Heat-induced fibrillation of BclXL apoptotic repressor. Biophys. Chem. 179 (2013), 12–25.
45. [45] Hottiger, T., De Virgilio, C., Hall, M.N., Boller, T., Wiemken, A., The role of trehalose synthesis for the acquisition of thermotolerance in yeast. II. Physiological concentrations of trehalose increase the thermal stability of proteins in vitro. Eur. J. Biochem. 219 (1994), 187–193.
46. [46] Sola-Penna, M., Meyer-Fernandes, J.R., Stabilization against thermal inactivation promoted by sugars on enzyme structure and function: why is trehalose more effective than other sugars?. Arch. Biochem. Biophys. 360 (1998), 10–14.
47. [47] Gagnon, P., Nian, R., Leong, D., Hoi, A., Transient conformational modification of immunoglobulin G during purification by protein A affinity chromatography. J. Chromatogr. A 1395 (2015), 136–142.
48. [48] Arosio, P., Rima, S., Lattuada, M., Morbidelli, M., Population balance modeling of antibodies aggregation kinetics. J. Phys. Chem. B 116 (2012), 7066–7075.
49. [49] Le Brun, V., Friess, W., Bassarab, S., Mühlau, S., Garidel, P., A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein–protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody. Eur. J. Pharm. Biopharm. 75 (2010), 16–25.
50. [50] Roberts, D., Keeling, R., Tracka, M., van der Walle, C.F., Uddin, S., Warwicker, J., et al. The role of electrostatics in protein–protein interactions of a monoclonal antibody. Mol. Pharm. 11 (2014), 2475–2489.